Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

Université de Montréal

$100,000.00

Distilled-DEL: A novel DNA-encoded drug discovery platform enabling biological evaluation of cellular targets on live cells.

FY 2023-24

Summary
One innovative strategy for discovering novel chemical matter that has emerged in recent years relies on the use of DNA barcoding to identify compounds in large chemical libraries. A major advantage of DNA-encoded libraries (DEL) is their unmet size and chemical coverage, with some libraries containing hundreds of millions of compounds. The current proposal aims at addressing obstacles to efficient DNA-enabled drug discovery. Leveraging our proprietary headpiece technology and using novel synthetic techniques, we will produce two libraries of over 30 million drug-like macrocycles of unprecedented integrity. Reduction in library contamination is expected to improve both reliability of sensitivity of downstream biological screens. To access a wider scope of DEL-compatible targets, and improve screening results's fidelity, we will develop cell-based DEL screening methodologies and apply them to therapeutic targets of relevance to breast cancer directly in cancer cell lines. Finally, to help guide hit development efforts further, we will develop DNA-based probes for target identification and active site mapping, and apply the method to the elucidation of the binding mode of UM171, a high-value pharmaceutical currently used clinically for stem cell transplantation. This research will have a significant impact on early drug discovery programs, especially those targeting cancer and emerging pathogens where access to high-quality hits devoid of false positives is essential and requires the screening of large libraries. It also offers an exceptional training opportunity for early career scientists and students who wish to pursue a career at the interface of medicinal chemistry and chemical biology, while addressing two areas of high clinical relevance: breast cancer and stem cell epigenetics.
Program
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
504793
Name
Marinier Anne
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Distilled-DEL: A novel DNA-encoded drug discovery platform enabling biological evaluation of cellular targets on live cells.
Programtype2
Operating Grants
Orgnameinp2
Université de Montréal
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Keyworddelim
Biased Signaling; Breast Cancer; Cancer Therapeutics; Cell-Based Screens; Dna-Encoded Chemical Libraries (Decl); Drug Discovery; Early Hits Identification; G-Protein Coupled Receptors (Gpcrs); Stem Cell Epigenetics; Target Identification And Active Site Mapping
Abstract
One innovative strategy for discovering novel chemical matter that has emerged in recent years relies on the use of DNA barcoding to identify compounds in large chemical libraries. A major advantage of DNA-encoded libraries (DEL) is their unmet size and chemical coverage, with some libraries containing hundreds of millions of compounds. The current proposal aims at addressing obstacles to efficient DNA-enabled drug discovery. Leveraging our proprietary headpiece technology and using novel synthetic techniques, we will produce two libraries of over 30 million drug-like macrocycles of unprecedented integrity. Reduction in library contamination is expected to improve both reliability of sensitivity of downstream biological screens. To access a wider scope of DEL-compatible targets, and improve screening results's fidelity, we will develop cell-based DEL screening methodologies and apply them to therapeutic targets of relevance to breast cancer directly in cancer cell lines. Finally, to help guide hit development efforts further, we will develop DNA-based probes for target identification and active site mapping, and apply the method to the elucidation of the binding mode of UM171, a high-value pharmaceutical currently used clinically for stem cell transplantation. This research will have a significant impact on early drug discovery programs, especially those targeting cancer and emerging pathogens where access to high-quality hits devoid of false positives is essential and requires the screening of large libraries. It also offers an exceptional training opportunity for early career scientists and students who wish to pursue a career at the interface of medicinal chemistry and chemical biology, while addressing two areas of high clinical relevance: breast cancer and stem cell epigenetics.
Competitiondate
202403
Approvedterm2
1 yr 0 mth
Pinamesdelim
Marinier, Anne
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~
Université de Montréal - $100,000 Grant (2023-24) | Canada Spends